Actively Recruiting
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Led by Irrua Specialist Teaching Hospital · Updated on 2026-02-04
1755
Participants Needed
4
Research Sites
108 weeks
Total Duration
On this page
Sponsors
I
Irrua Specialist Teaching Hospital
Lead Sponsor
A
Alliance for International Medical Action
Collaborating Sponsor
AI-Summary
What this Trial Is About
Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%. Transmission to humans occurs mainly via direct or indirect exposure to excreta from the rodent reservoir, mainly made up of Mastomys natalensis . Less frequently, LASV may also be transmitted from human to human and cause nosocomial outbreaks. Ribavirin is the only treatment available with worrying toxicity, questionable efficacy and low access because of its high cost. Consequently, there is an urgent need for new drugs to treat LF patients. The Research and Development (R\&D) Blueprint of the World Health Organization (WHO) has included LF in the list of priority diseases for urgent research and development. The INTEGRATE consortium is an unprecedented international collaboration on Lassa fever of 15 partners from 10 countries across West Africa, Europe and North America and across several disciplines (epidemiological researchers, social scientists, medical health facility professionals, humanitarian actors, etc.).
CONDITIONS
Official Title
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical disease with signs and symptoms suggestive for Lassa fever
- Positive plasma LASV RT-PCR
- Participant requires hospitalization per local guidelines
- Ability and willingness of participant or legally authorized representative to sign informed consent
- Age 18 years or older for Favipiravir sub-protocols
- Age 12 years or older for Dexamethasone sub-protocol
You will not qualify if you...
- Unwilling to provide informed consent
- Positive pregnancy test
- History of allergic reaction or contraindication to ribavirin
- Received drug therapy for Lassa fever (excluding supportive care) before inclusion
- Previous vaccination against Lassa fever
- For Favipiravir sub-protocols: treatment contraindicated with Favipiravir, pre-existing liver failure, severe gout or hyperuricemia, history of QT prolongation or arrhythmia or cardiac disorders, PR interval ≥ 200 ms, hypersensitivity to excipients, inability to take oral drug
- For Dexamethasone sub-protocol: known intolerance or contraindications to ribavirin or dexamethasone, corticosteroid use within preceding 7 days
- For ARN-75039 sub-protocols: history of severe gastrointestinal disease, chronic generalized pruritus, severe chronic liver disease, severe cardiac disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Phebe Hospital
Suacoco, Bong County, Liberia
Not Yet Recruiting
2
Irrua Specialist Teaching Hospital
Irrua, Edo, Nigeria
Actively Recruiting
3
Federal Medical Center Owo
Owo, Ondo State, Nigeria
Actively Recruiting
4
Abubakar Tafawa Balewa University Teaching Hospital
Bauchi, Nigeria
Not Yet Recruiting
Research Team
C
Camille FRITZELL, PHD
CONTACT
S
Sylvain JUCHET
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here